MA54464A - Anticorps humanisé anti-récepteur de l'igf-i - Google Patents
Anticorps humanisé anti-récepteur de l'igf-iInfo
- Publication number
- MA54464A MA54464A MA054464A MA54464A MA54464A MA 54464 A MA54464 A MA 54464A MA 054464 A MA054464 A MA 054464A MA 54464 A MA54464 A MA 54464A MA 54464 A MA54464 A MA 54464A
- Authority
- MA
- Morocco
- Prior art keywords
- igf
- humanized anti
- receptor antibody
- antibody
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018226669 | 2018-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54464A true MA54464A (fr) | 2021-10-20 |
Family
ID=70974206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054464A MA54464A (fr) | 2018-12-03 | 2019-12-02 | Anticorps humanisé anti-récepteur de l'igf-i |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12227563B2 (fr) |
| EP (1) | EP3895732A4 (fr) |
| JP (2) | JP7246409B2 (fr) |
| KR (1) | KR102771846B1 (fr) |
| CN (1) | CN113286612B (fr) |
| AR (1) | AR117673A1 (fr) |
| AU (1) | AU2019393487B2 (fr) |
| BR (1) | BR112021010479A2 (fr) |
| CL (1) | CL2021001446A1 (fr) |
| CO (1) | CO2021007229A2 (fr) |
| IL (1) | IL283099B2 (fr) |
| MA (1) | MA54464A (fr) |
| MX (1) | MX2021006495A (fr) |
| MY (1) | MY205006A (fr) |
| PH (1) | PH12021551210A1 (fr) |
| SG (1) | SG11202105714UA (fr) |
| TW (1) | TWI850288B (fr) |
| WO (1) | WO2020116398A1 (fr) |
| ZA (1) | ZA202103350B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296519A (en) * | 2020-06-02 | 2022-11-01 | Teijin Pharma Ltd | Anti-igf-1 receptor humanized antibody |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025240847A1 (fr) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
| WO2026090116A2 (fr) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (fr) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs ras pour traiter un cancer |
| WO2026106912A1 (fr) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026112260A1 (fr) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026122764A2 (fr) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026128688A2 (fr) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026161839A1 (fr) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Inhibiteurs de ras |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ527302A (en) | 2001-01-05 | 2006-10-27 | Abgenix Inc | Antibodies to insulin-like growth factor I receptor |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| KR20050021001A (ko) * | 2002-06-14 | 2005-03-04 | 이뮤노젠 아이엔씨 | 인간 인슐린-유사 성장인자-i 수용체 항체 |
| FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| WO2008079849A2 (fr) * | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Anticorps liés au récepteur du facteur de croissance semblable à l'insuline |
| WO2009121759A2 (fr) | 2008-04-03 | 2009-10-08 | F. Hoffmann-La Roche Ag | Utilisation de variants de igf-i pegylés pour traiter des troubles neuromusculaires |
| AR105553A1 (es) * | 2015-04-27 | 2017-10-18 | Pf Medicament | Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer |
| JP6096267B1 (ja) | 2015-12-09 | 2017-03-15 | 上銀科技股▲分▼有限公司 | ボールねじに用いる防塵ユニット |
| CA3056573A1 (fr) * | 2017-05-30 | 2018-12-06 | Teijin Pharma Limited | Anticorps anti-recepteur igf-i |
-
2019
- 2019-12-02 WO PCT/JP2019/047050 patent/WO2020116398A1/fr not_active Ceased
- 2019-12-02 MY MYPI2021002881A patent/MY205006A/en unknown
- 2019-12-02 MX MX2021006495A patent/MX2021006495A/es unknown
- 2019-12-02 SG SG11202105714UA patent/SG11202105714UA/en unknown
- 2019-12-02 AR ARP190103516A patent/AR117673A1/es unknown
- 2019-12-02 JP JP2020559184A patent/JP7246409B2/ja active Active
- 2019-12-02 EP EP19892830.1A patent/EP3895732A4/fr active Pending
- 2019-12-02 KR KR1020217016909A patent/KR102771846B1/ko active Active
- 2019-12-02 TW TW108143925A patent/TWI850288B/zh active
- 2019-12-02 IL IL283099A patent/IL283099B2/en unknown
- 2019-12-02 BR BR112021010479A patent/BR112021010479A2/pt unknown
- 2019-12-02 US US17/299,383 patent/US12227563B2/en active Active
- 2019-12-02 AU AU2019393487A patent/AU2019393487B2/en active Active
- 2019-12-02 MA MA054464A patent/MA54464A/fr unknown
- 2019-12-02 CN CN201980079892.XA patent/CN113286612B/zh active Active
-
2021
- 2021-05-18 ZA ZA2021/03350A patent/ZA202103350B/en unknown
- 2021-05-26 PH PH12021551210A patent/PH12021551210A1/en unknown
- 2021-05-31 CO CONC2021/0007229A patent/CO2021007229A2/es unknown
- 2021-06-02 CL CL2021001446A patent/CL2021001446A1/es unknown
-
2022
- 2022-11-01 JP JP2022175717A patent/JP2023011808A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210088625A (ko) | 2021-07-14 |
| CO2021007229A2 (es) | 2021-08-19 |
| CN113286612B (zh) | 2024-12-24 |
| MX2021006495A (es) | 2021-07-06 |
| IL283099B1 (en) | 2024-10-01 |
| ZA202103350B (en) | 2022-08-31 |
| CA3120740A1 (fr) | 2020-06-11 |
| AR117673A1 (es) | 2021-08-25 |
| KR102771846B1 (ko) | 2025-02-21 |
| US20220033485A1 (en) | 2022-02-03 |
| US12227563B2 (en) | 2025-02-18 |
| TW202039559A (zh) | 2020-11-01 |
| JP2023011808A (ja) | 2023-01-24 |
| CL2021001446A1 (es) | 2022-01-14 |
| MY205006A (en) | 2024-09-27 |
| JP7246409B2 (ja) | 2023-03-27 |
| PH12021551210A1 (en) | 2021-11-08 |
| TWI850288B (zh) | 2024-08-01 |
| EP3895732A1 (fr) | 2021-10-20 |
| WO2020116398A1 (fr) | 2020-06-11 |
| BR112021010479A2 (pt) | 2021-11-16 |
| JPWO2020116398A1 (ja) | 2021-09-30 |
| IL283099A (en) | 2021-06-30 |
| CN113286612A (zh) | 2021-08-20 |
| SG11202105714UA (en) | 2021-06-29 |
| AU2019393487A1 (en) | 2021-06-03 |
| AU2019393487B2 (en) | 2026-05-14 |
| EP3895732A4 (fr) | 2022-09-14 |
| IL283099B2 (en) | 2025-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202103350B (en) | Anti-igf-i receptor humanized antibody | |
| EP4159860A4 (fr) | Anticorps humanisé de récepteur anti-igf-1 | |
| IL270971A (en) | Antibody against the 1-IGF receptor | |
| MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
| MA52212A (fr) | Anticorps multivalent | |
| EP4017883A4 (fr) | Nouveaux anticorps anti-cldn18.2 | |
| IL281428A (en) | Chimeric antigen receptor | |
| EP3765522A4 (fr) | Anticorps anti-claudine 18.2 | |
| MA52366A (fr) | Anticorps anti-tl1a optimisés | |
| LT3762380T (lt) | Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai | |
| MA49270A (fr) | Récepteurs de liaison à l'antigène améliorés | |
| EP3938401A4 (fr) | Récepteurs d'antigènes chimériques anti-bcma | |
| IL280003A (en) | Anti-mesothelin antibodies | |
| EP4032907A4 (fr) | Anticorps et récepteur antigénique chimérique ciblant bcma | |
| IL276836A (en) | Cd83-binding chimeric antigen receptors | |
| EP3752536A4 (fr) | Anticorps anti-her2 | |
| MA51903A (fr) | Formulations d'anticorps b7-h4 | |
| EP3806903A4 (fr) | Récepteurs antigéniques chimériques anti-cd79a | |
| IL289899A (en) | Anti-hk2 chimeric antigen receptor (car) | |
| IL284807A (en) | Antibodies specific to human nectin-2 | |
| EP3746421A4 (fr) | Antagonistes du récepteur muscarinique de l'acétylcholine m4 | |
| MA53218A (fr) | Antagonistes de l'intégrine | |
| EP3825334A4 (fr) | Anticorps monoclonal humanisé anti-her3 | |
| MA51902A (fr) | Schémas posologiques d'anticorps b7-h4 | |
| EP3885362A4 (fr) | Conjugué d'anticorps |